Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion
EFC14462
Phase 3 small_molecule active
Quick answer
Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion for Glycogen storage disease type II is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Glycogen storage disease type II
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active